在多发性骨髓瘤中代谢无声的扩散性肝参与:一个F-FDG-PET/CT陷
Seçkin Bilgiç1, Merve Okuyan2, Efrah İbrahim1
1Bursa Uludağ University Faculty of Medicine, Department of Nuclear Medicine, Bursa, Türkiye.
Molecular imaging and radionuclide therapy
|March 6, 2026
概括
在多发性骨髓瘤中,扩散性肝脏参与是罕见的. 这个案例显示了18F-FDG PET/CT在检测它的局限性,突出了综合诊断的需要.
科学领域:
- 在瘤学瘤学.
- 医疗成像医学成像
- 血液学 血液学 血液学
背景情况:
- 多发性骨髓瘤中扩散性肝脏参与是一种不常见的表现.
- 它可能会带来诊断挑战,特别是使用先进的成像技术.
- 早期和准确的诊断对于有效的管理至关重要.
研究的目的:
- 报告一种罕见的多发性骨髓瘤扩散性肝脏干扰病例.
- 为了说明18F-氧葡萄糖正子发射断层扫描/计算机断层扫描 (18F-FDG PET/CT) 在诊断这种疾病方面的局限性.
- 强调多式联通诊断方法的重要性.
主要方法:
- 一个59岁的男性,有多发性骨髓瘤病史的病例介绍.
- 使用18F-FDG PET/CT来评估肝脏和骨的参与.
- 进行肝脏活检以进行组织病理学检查.
- 对全身疗法的监测反应.
主要成果:
- 这位患者呈现出肝壮病和.
- 18F-FDG PET/CT显示肝脏扩散,但肝脏没有显著的18F-FDG吸收,表明低代谢性髓瘤表型.
- 肝脏活检证实了血细胞的扩散性鼻状透,不包括粉样化症.
- 肝炎和瘤随着治疗而消失,但肝脏18F-FDG吸收仍然不存在.
结论:
- 18F-FDG PET/CT在检测扩散性肝髓瘤方面可能受到限制.
- 形态和代谢发现之间的不一致性需要进一步调查.
- 多种模式的诊断策略,包括活检,对于肝髓瘤的准确诊断和管理至关重要.
更多相关视频
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
6.9K
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
9.1K
相关概念视频
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
273
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
273
01:20Myasthenia Gravis: Overview and Treatment
3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K